Incannex to Begin Investigational New Drug Opening Trial of IHL-42X in OSA

Incannex Healthcare Ltd, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies, has received approval from the US Food and Drug Administration (FDA) for an Investigational New Drug (IND) opening pivotal IHL-42X phase 2/3 clinical trial for obstructive sleep apnea in the United States as planned. Incannex submitted the IND application…

Read More

Remote Mask Fitters Enhance Care for Established CPAP Users

By Alyx Arnett Remote CPAP mask-fitting technology emerged as a lifeline during the COVID-19 pandemic, allowing patients to be fitted for masks—a process traditionally requiring in-person visits—safely from their homes.  Introduced as a solution to the challenges of providing essential services amid social distancing, the software solutions now show longer-term utility. Beyond facilitating initial fittings,…

Read More

Mechanisms Behind Melatonin’s Memory-Enhancing Effects Unveiled

Multiple studies have demonstrated the memory-enhancing effects of melatonin and its derivatives in animal models. It is also known that the formation of both short- and long-term memories requires the phosphorylation of certain memory-related proteins. However, the molecular mechanisms underlying melatonin-induced memory enhancement have remained elusive.  Now, medical researchers from Sophia University, Japan, have made…

Read More

The Overdue Need to Study Sleep’s Role in Huntington’s Disease

In individuals with Huntington’s disease (HD), sleep disturbances constitute an additional burden that may exacerbate disease outcomes and impact patients’ quality of life. A special issue of the Journal of Huntington’s Disease reviews what is and, perhaps more importantly, what is not known about sleep and circadian rhythms in HD. Disrupted sleep can alter metabolism…

Read More